Abstract

Recurrent tuberculosis (TB), defined as TB that recurs after a patient has been considered cured, constitutes a challenge to TB control. In low TB burden countries, the underlying causes and consequences of recurrent TB are poorly understood. We conducted a literature review to summarise the evidence of recurrent TB in low-burden settings and to address current gaps in knowledge. We included peer-reviewed publications on studies conducted in countries with an estimated TB incidence of <100 cases per 100 000 population. The Newcastle-Ottawa scale was used to assess study quality. The review yielded 44 manuscripts, 39 of which were reports of observational studies and 5 of clinical trials. The median percentage of TB patients experiencing an episode of recurrent TB after treatment completion was 3.4% (interquartile range [IQR] 1.6-6.0, range 0.4-16.7) in studies with a median follow-up of 7.8 years (IQR 5-12, range 2-33). The median percentage of recurrences attributable to endogenous reactivation (rather than exogenous reinfection) was 81% (IQR 73.1-85.5, range 49-100). Commonly identified risk factors for recurrence in low-burden settings included infection by the human immunodeficiency virus, low socio-economic status, foreign birth and infection with drug-resistant TB. Current understanding of recurrence in low-burden settings is limited, in part due to substantial methodological differences between studies. Further research is required to delineate the mechanisms of TB recurrence, its health and clinical impact, as well as the implications for TB elimination efforts in low-burden countries.

Highlights

  • In 2015, worldwide an estimated 10.4 million people developed tuberculosis (TB), and 1.8 million died from TB, including 0.4 million co-infected with the Human ImmunodeficiencyVirus (HIV) (1)

  • An important outcome measure for global TB control is the percentage of treated TB patients who successfully complete their treatment, including those with bacteriological proof of cure and those who complete their treatment in the absence of either proof of bacteriological cure or of treatment failure

  • Global TB control efforts have resulted in an increase in the treatment success rate for new cases globally from 69% in 2000 to 84% 2005; between 2006 to 2014, rates have ranged between 83% and 87% (1)

Read more

Summary

Introduction

In 2015, worldwide an estimated 10.4 million people developed tuberculosis (TB), and 1.8 million died from TB, including 0.4 million co-infected with the Human ImmunodeficiencyVirus (HIV) (1). In 2015, worldwide an estimated 10.4 million people developed tuberculosis (TB), and 1.8 million died from TB, including 0.4 million co-infected with the Human Immunodeficiency. Considerable progress has been made in global TB control over the past two decades. Significant advances in TB diagnosis, treatment and control have reduced global TB prevalence in 2015 by 42% and mortality by 47% relative to 1990 levels (1). An important outcome measure for global TB control is the percentage of treated TB patients who successfully complete their treatment, including those with bacteriological proof of cure and those who complete their treatment in the absence of either proof of bacteriological cure or of treatment failure. Global TB control efforts have resulted in an increase in the treatment success rate for new cases globally from 69% in 2000 to 84% 2005; between 2006 to 2014, rates have ranged between 83% and 87% (1)

Objectives
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call